

Curriculum Vitae

RAJ S. PRUTHI

Education:

- 1984-88 Stanford University, Stanford, California
B.S. in Biology and B.A. in Economics with Honors, June, 1988
- 1988-92 Duke University School of Medicine, Durham, North Carolina
M.D., May, 1992

Professional Training:

- 1992-93 Stanford University, Stanford, California
Internship, General Surgery
- 1993-94 Stanford University, Stanford, California
Residency, General Surgery
- 1994-98 Stanford University, Stanford, California
Residency, Urology
- 1995-96 Stanford University, Stanford, California
Fellow, Prostate cancer and Ultrasonography, Dept. of Urology

Employment History:

- 5/2006 – present Division of Urology, UNC School of Medicine, Chapel Hill, NC
Associate Professor of Surgery (tenure)
- 4/2000 – 5/2006 Division of Urology, UNC School of Medicine, Chapel Hill, NC
Assistant Professor of Surgery
- 4/1999– 4/2000 Dept. of Urology, LSU Medical Center, Shreveport, Louisiana
Assistant Professor of Urology
- 8/1998 – 4/1999 Kinston Urological Associates, Kinston, North Carolina
Private Practice of Urology

Board Certification/Licensure:

- North Carolina Medical Board 1998
Louisiana State Board of Medical Examiners 1999
Drug Enforcement Agency 1993
American Board of Urology 2002

Memberships/Societies

American Urological Association (1996 – present)
Southeast Section - American Urological Association (1998 – present)
Society of Urologic Oncology (2002 – present)
American College of Surgeons (2003-present)
Triangle Urological Society (2000 – present)
American College of Surgeons Oncology Group (2000 – present)
Cancer and Leukemia Group B – Genitourinary core member (2000 – present)

Teaching / Professional Appointments:

National / International

Core Member, Genitourinary Committee – Cancer and Leukemia Group B (CALGB), 10/00 - present

Surgical Principal Investigator, University of North Carolina -- Cancer and Leukemia Group B (CALGB), 7/05 - present

Panel Member, Bladder Cancer Clinical Guidelines, *American Urological Association*, 6/04 - present

Invited Member, Urological Research Society, 11/05 – present

Member, American College of Surgeons Committee on Young Surgeons, 5/07 - present

Member, Young Urologists Committee, American Urological Association, 6/07 - present

Member, Young Urologists Leadership Committee, Southeastern Section of the American Urological Association, 3/07 - present

Consultant, *Journal of Urology*, 1/02 - present

Consultant, *Urology*, 6/03 - present

Consultant, *Urologic Oncology*, 1/03 - present

Consultant, *British Journal of Urology*, 1/05 - present

Consultant, *European Urology*, 6/05 - present

Consultant, *Apoptosis*, 10/04 - present

Consultant *Journal of Endourology*, 1/06 – present

Consultant *Cancer*, 3/06 - present

Consultant *Archives of Medical Research*, 3/06 - present

Consultant *TSW Urology*, 11/06 – present

Consultant *International Brazilian Journal of Urology*, 3/07 – present

Consultant *Indian Journal of Urology*, 2/07 – present

Consultant *Issues in Urology*, 3/07 – present

Consultant *Lancet Oncology*, 3/07 – present

Consultant *Expert Opinion on Pharmacotherapy*, 3/07 – present

Consultant *Journal of Womens Health*, 9/07 – present

Consultant *Expert Review of Anticancer Therapy*, 9/07 – present

Editorial Board, *Prostate Cancer and Prostatic Diseases*, 3/05 – present

Editorial Board, *World Journal of Urology*, 11/07 - present

Editorial Advisory Board, *Contemporary Urology*, 1/02 - present

Local/Regional

Head, Section of Urologic Oncology; Division of Urologic Surgery - UNC School of Medicine,
2/03 – present

Director of Urologic Resident Education - UNC School of Medicine, 1/01 – present

Co-director, Multidisciplinary Clinic in Genitourinary Oncology - UNC School of Medicine,
10/00 – present

Director of Ambulatory Care, Department of Surgery UNC School of Medicine, 11/02 – present

Disease Group Leader, Urologic Oncology, Lineberger Comprehensive Cancer Center - UNC
School of Medicine, 1/03 – 1/07

Member, Executive Committee - North Carolina Cancer Hospital - UNC School of Medicine,
11/06 – present.

Member, Regional Strategies Working Group - North Carolina Cancer Hospital - UNC School of
Medicine, 1/07 – present.

Lecturer - medical students, urology residents on urologic surgery, retroperitoneal/pelvic
anatomy (UNC School of Medicine, 4/00 – present); (LSU School of Medicine, 7/99 – 4/00)

Clinical Teaching - urology residents (UNC School of Medicine, 4/00 – present); (LSU School of Medicine, 7/99 – 4/00)

Attending - urology clinical service (UNC School of Medicine, 4/00 – present); (LSU School of Medicine, 7/99 – 4/00)

Member, Lineberger Comprehensive Cancer Center - UNC School of Medicine, 7/00 – present

Member, Protocol Review Committee, Lineberger Comprehensive Cancer Center - UNC School of Medicine, 7/00 – present

Member, Operating Room Advisory Committee, UNC School of Medicine, 1/01 - present

Member, Surgery Quality Assurance Committee, UNC School of Medicine, 1/02 - present

Member, Surgical Endoscopy Committee, UNC School of Medicine, 7/00 – present

Member, Laparoscopic Institute of North Carolina, UNC School of Medicine, 7/00 – present

Team leader, Clinical Research Team, Division of Urology - UNC School of Medicine, 8/00 – present

Unit Chief, Urology Inpatient Service - UNC School of Medicine, 12/00 – present

Member, Compensation Task Force, Department of Surgery - UNC School of Medicine, 7/02 – present

Member, Multidisciplinary Team Evaluating Medication Errors - UNC School of Medicine, 10/02 – 2/03

Publications:

1. Csernansky, J.G., Kerr, S., **Pruthi, R.S.**, Prosser, E.S.: Mesolimbic dopamine receptor increases two weeks after hippocampal kindling. *Brain Research*, 449:357-60, 1988.
2. Prosser, E.S., **Pruthi, R.S.**, Csernansky, J.G.: Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. *Psychopharmacology*, 99: 109-16, 1989.
3. Meyers, W.C., Farouk, M., **Pruthi, R.S.**, et al. (Southern Surgeon's Club): A prospective analysis of 1518 laparoscopic cholecystectomies. *New England Journal of Medicine*, 324: 1073-8, 1991.
4. Farouk, M., **Pruthi, R.S.**, Meyers, W.C.: The appearance and characterization of intrahepatic secretin receptors following common bile duct ligation. *Surgical Forum*, 42: 156-9, 1991.
5. **Pruthi, R.S.**, Farouk, M., Meyers, W.C.: Somatostatin analogue inhibits hepatic regeneration. *Surgical Forum*, 42: 144-7, 1991.

6. Farouk, M., Geoghegan, J.G., **Pruthi, R.S.**, Pappas, T.N., Meyers, W.C.: ICV neuropeptide Y stimulates bile duct secretion via a vagal mechanism. *Gut*, 33: 1562-5, 1992.
7. **Pruthi, R.S.**, Farouk, M., Tsai, W.S., Michalopoulos, G., Meyers, W.C.: The effect of octreotide on liver regeneration in the rat. *Surgery*, 113: 84-9, 1993.
8. Farouk, M., **Pruthi, R.S.**, Vigna, S.V., Haebig, J.A., Meyers, W.C: Characterization of the secretin receptor expressed by rat bile duct epithelium. *Journal of Surgical Research*, 54:1-6, 1993.
9. **Pruthi, R.S.**, Angell, S.A., Dubocq, F., Merguerian, P.A., Shortliffe, L.D.: Use of longitudinal renal parenchymal area in children with high grade vesicoureteral reflux. *Pediatrics*, 98 (3): 619, 1996.
10. Angell, S.A., **Pruthi, R.S.**, Freiha F.S.: A primary thyroid-like carcinoma of the kidney. *Urology*, 48 (4): 632-5, 1996.
11. **Pruthi, R.S.**, Angell, S.K., Gill, H.: Furuncular myiasis of the scrotum. *Infections in Urology*, 10 (4): 102-4, 1997.
12. Angell, S.A., **Pruthi, R.S.**, Merguerian, P.A.: Pediatric Genitourinary Tumors. *Current Opinions in Oncology*, 8:240-6, 1996.
13. **Pruthi, R.S.**, Angell, S.A., Dubocq, F., Merguerian, P.A., Shortliffe, L.D.: The use of renal parenchymal area in children with vesicoureteral reflux. *Journal of Urology* 158: 1232-5, 1997
14. **Pruthi, R.S.**, Haese, A., Huland, E., Stamey, T.A.: The use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. *Urology*, 49 (3), 404-10, 1997.
15. **Pruthi, R.S.**, Tu, I-P, Johnstone, I., Stamey, T.A.: PSA doubling times in patients who fail radical prostatectomy: correlation with histology of the primary cancer. *Urology*, 49(5), 737-42, 1997.
16. Issa, M.M., McNamara, D., **Pruthi, R.S.**: A new method for stenting impacted ureteral stones: the glidewire loop technique. *Urology*, 49 (4), 614-7, 1997.
17. Issa, M.M., **Pruthi, R.S.**, Vial, C., Terris, M.K.: An unusual complication following uroflowmetry: hyponatremia and seizure. *Urologia Internationalis*, 59(2), 129-30, 1997
18. **Pruthi, R.S.**: Regarding recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. *Journal of Urology* 159(5), 1650, 1998.
19. Angell, S.A., **Pruthi, R.S.**, Shortliffe, L.D.: The urodynamic relationship of renal pelvic and bladder pressures, and urinary flow rate in rats with congenital vesicoureteral reflux. *Journal of Urology*, 160(1), 15-6, 1998.

20. **Pruthi, R.S.**, Terris, M.K., Issa, M.I., Kabalin, J.K.: Renal masses presenting 25 and 50 years following renal trauma. *Urologia Internationalis* , 61(1), 43-6, 1998.
21. Angell, S.A., **Pruthi, R.S.**, Gill, H.: A testicular teratoma with a unique mode of spread. *Urologia Internationalis*, 61(2), 119-20, 1998.
22. **Pruthi, R.S.**, Angell, S.A., Brooks, J.D., Gill, H.G.: Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein. *British Journal of Urology*, 83(1), 142-3, 1999.
23. **Pruthi, R.S.**: The value of urine cytology in the diagnosis and management of urinary tract malignancies. *Pathology Case Reviews*, 5(2), 102-5, 2000.
24. **Pruthi, R.S.**, Petrus, C.D., Nidess, R., Venable, D.D.: Penile fracture of the proximal corporal body. *Journal of Urology*, 164(2), 447-8, 2000.
25. **Pruthi, R.S.**: PSA Kinetics: A review of PSA doubling times and half-lives in patients with treated and untreated prostate cancer. *The Prostate Journal*, 2(4), 2000.
26. Petrus, C.D., **Pruthi, R.S.**: Crossed renal ectopia with an associated ureteral stone: sonographic, CT, and pyelographic findings. *Infections in Urology*, 13(6), 159-62, 2000.
27. **Pruthi, R.S.**: A review of PSA dynamics in benign and malignant diseases of the prostate. *British Journal of Urology* 86(6), 652-8, 2000.
28. **Pruthi, R.S.**, Petrus, C.D., and Bundrick, S.: "Neovesicovaginal fistula formation after transurethral collagen injection in women who have undergone cystectomy and orthotopic neobladder: presentation and definitive treatment." *Journal of Urology*, 164(5), 1638-9, 2000.
29. **Pruthi, R.S.**: Regarding Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. *Journal of Urology*, 164(6), 2031, 2000.
30. Ornstein, D.K., and **Pruthi, R.S.**: Prostate-specific antigen. *Expert Opinion in Pharmacotherapy*, 1(7), 1399-1411, 2000.
31. **Pruthi, R.S.**, Richman, M., Ornstein D.K.: A case of T1c, N3, M1 prostate cancer. *Urology International*, 69(1), 82-4, 2002.
32. **Pruthi, R.S.**, Kang J, Vick, R. Desmopressin-induced hyponatremia and seizures after laparoscopic radical nephrectomy. *Journal of Urology*, 168, 67, 2002.
33. Chun J., **Pruthi R.S.**: The role of neoadjuvant hormonal therapy before radical prostatectomy. *The Prostate Journal*, 4(4), 86-90, 2002.
34. **Pruthi, R.S.**, Issa M.M., Fielding J.: Evaluation and Treatment of the Incidental Adrenal Mass. *Contemporary Urology* April. 43-55, 2003.

35. **Pruthi R.S.**, Chun J., Richman M.: Regarding Hand-assisted laparoscopic nephrectomy: complications related to the handport site. *BJU Int* 91(6):584, 2003.
36. **Pruthi R.S.**, Gaston K., Derksen J.E.: Regarding Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. *Journal of Urology*, 169, 2304-5, 2003.
37. **Pruthi R.S.**, Derksen JE, Gaston K.: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. *Journal of Urology*, 169, 2352-9, 2003.
38. Small E, **Pruthi R.S.**, Bajorin D, Dalbagni G, Phillips G, Halibi S, Edelman M. Overview of Bladder Cancer Trials in the Cancer and Leukemia Group B. *Cancer*. 97(8 Suppl): 2090-8, 2003.
39. Derksen J.E., Fitzsimmons N., Ornstein D., **Pruthi R.S.**: Early urethral catheter removal after radical retropubic prostatectomy. *Journal of the American College of Surgeons*, 197 (3 Suppl): S92, 2003
40. **Pruthi R.S.**: PSA doubling time may point to cancer aggressiveness. *Urology Times*. 31(3), 32, 2003.
41. Gaston K., Lee K., **Pruthi R.S.**: Impact of race, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in sibling of patients with prostate cancer. *Journal of the American College of Surgeons*, 197 (3 Suppl): S92, 2003
42. **Pruthi R.S.**, Chun J., Richman M.: Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy. *Urology*, 62, 661-5, 2003.
43. **Pruthi R.S.**, Derksen J.E, Richman M: Stage I renal cell carcinoma relapsing in the vagina 10 years after initial diagnosis. *Journal of Urology* 170, 2379-81, 2003.
44. **Pruthi R.S.**, Derksen J.E. Use of the COX-2 inhibitor celecoxib in PSA-recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, 6 (Suppl 1): S30, 2003.
45. Richman M., Moliterno J., **Pruthi R.S.**: Retroperitoneal Cyst of the Lienorenal Ligament. *Urology*. 63: 379, 2004.
46. Gaston K, **Pruthi R.S.**: Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve. *Journal of Urology*, 171; 63-7, 2004.
47. Derksen E., **Pruthi, R.S.**: COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. *BJU Int*. 93: 275-8, 2004.
48. Chun J., **Pruthi R.S.**: Is neoadjuvant hormonal therapy before radical prostatectomy indicated? *Urol Int*. 72:275-80, 2004.
49. **Pruthi R.S.**, Chun J., Richman M.: Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. *BJU Int*. 93:813-7, 2004.

50. Gaston K, **Pruthi R.S.**: The use of urinary cytology in the diagnosis and management of urinary tract malignancies. *Urology*. 63:1009-16, 2004.
51. Kang, J., Mohler, J.L., **Pruthi, R.S.**: Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. *BJU Int*. 93:1207-10, 2004.
52. Kouba E., Tornehl C., Wallen E., **Pruthi R.S.**: Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicalyceal bond integrity in a live porcine and isolated abattoir animal model. *Journal of Urology*. 172: 326-30, 2004.
53. Smith J.A., Cookson M., Hall M.C., Keane T.E., **Pruthi R.S.**: Confronting a rising PSA after prostatectomy. *Contemporary Urology* 16: 34-46, 2004.
54. Richman M., **Pruthi R.S.**: The potential role of early incision of the lateral pelvic fascia, development of a "perirectal pocket", and early ligation of the lateral pedicles in reducing positive margins after radical retropubic prostatectomy. *BJU Int*. 95:40-5, 2005.
55. **Pruthi R.S.**, Gaston K., Derksen JE, Wallen E.W. Rationale for the use of COX-2 inhibitors in bladder cancer. *Urology*, 64:637-42, 2004.
56. Stefaniak H.M., Wallen E., **Pruthi R.S.** The contribution of race to prostate cancer outcome – tumor biology versus socioeconomic and behavioral factors. *Contemporary Urology*. April 2005, 66-70.
57. Richman M, **Pruthi R.S.**: Laparoscopic Excision of Parapelvic Renal Cyst Causing Obstructive Uropathy. *Issues in Urology*. September 2005, pp.1-4.
58. Kouba E., Evans A.J., Gaston K., Wallen E.W., **Pruthi R.S.** Cystitis, carcinoma, and the use of urinary cytology. *Issues in Urology* (accepted/in press) pp.1-7.
59. Maygarden S.J., **Pruthi R.S.** Gleason grading and volume estimation in prostate needle biopsies: evolving issues. *Am J Clin Pathol*. 2005 Jun; 123 Suppl: S58-66
60. Hubbard JS, **Pruthi R.S.**, Wallen E.M.: A guide to understanding and minimizing the complications of laparoscopic urologic surgery. *Contemporary Urology*. October, 2005. p. 46-51.
61. **Pruthi R.S.** Editorial Comment in re: Long-term benefit of 5-Aminolevulinic acid-fluorescence-assisted transurethral resection of superficial bladder cancer: five-year results of a prospective randomized study. *Journal of Urology*. 175: 2291-91, 2005.
62. **Pruthi R.S.**, Tornehl C., Gaston K., Lee, K., Carson C., Wallen E. Impact of race, age, income and residence on prostate cancer knowledge. Screening and health maintenance in siblings of patients with prostate cancer. *European Urology* 2005 Dec 12.
63. **Pruthi R.S.**, Wallen E. Cyclooxygenase-2: a therapeutic target for prostate cancer. *Clin Genitourin Cancer*. 2005 Dec; 4(3):203-11.

64. Smith J.A., Cookson M., Hall M.C., Keane T.E., **Pruthi R.S.**: Confronting a rising PSA after prostatectomy. *Patient Care* December 2005, pp. 16-22.
65. **Pruthi R.S.** Editorial Comment in re: Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia and renal cell carcinoma. *European Urology*. 2006 Jul; 50(1):92-7.
66. **Pruthi R.S**, Kouba E., Carson CC., Wallen E. Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise. *Urology*. 2006 Nov; 68(5):917-23.
67. Derksen J.E., **Pruthi R.S.**: A case of urachal adenocarcinoma in a young female treated with partial cystectomy. *Issues in Urology* 18, Jan/Feb 2006, pp.14-17.
68. **Pruthi R.S**, Kouba E., Hubbard JS, Funkhouser W., Wallen E. Short Survey: Large Presacral Schwannoma after Radical Prostatectomy. *European Urology* 49, May 2006, Pages 914-917.
69. **Pruthi R.S**, Kouba E., Hubbard JS, Funkhouser W., Wallen E. Large Presacral Schwannoma after Radical Prostatectomy: Part 2. *European Urology* 49, June 2006, Pages 968-971.
70. Moliterno J, Evans A., Ornstein D.K., Mohler J.L., **Pruthi R.S.**: Characterization of post-operative PSA doubling times and recurrence times in patients who fail radical prostatectomy. *Urol Int*. 2006; 77(2):130-4.
71. Gaston K., **Pruthi R.S.**: The use of erythropoietin in patients undergoing radical prostatectomy: effects on hemtocrit, transfusion rates, and quality of life. *Urol Int Urol Int*. 2006; 77(3):211-5.
72. Fielding JR, Borland D, Lee KH, Clarke JP, Wallen E, **Pruthi R**, Taylor RM. Virtual pyeloscopy using volumetric depth peeling. *Acad Radiol*. 2006 Jun; 13(6):759-63.
73. **Pruthi R.S**, Kouba E., Hubbard JS, Wallen E Incisional Hernia in a 12 mm Non-Bladed Trocar Site Following Laparoscopic Nephrectomy. *TSW Urology*. March 2006 pp 104-107.
74. Gaston K.E., **Pruthi R.S.**: Racial Differences in Prostate Cancer. *NC Medical Journal*. March/April 2006 67(2):130-5.
75. **Pruthi R.S.**: Editorial Comment in re: Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. *J Urol*. 2006 Sep; 176(3):979-84; discussion 984.
76. Thomas R., Albala, D.M., Castle, E.P., **Pruthi, R.S.**: Symposium: Robotic surgery in urology: Hype, hope, and reality. *Contemporary Urology*. August 2006. p. 26-32.
77. McLaughlin S., Shephard J, Wallen E, Maygarden S, Carson CC, **Pruthi R.S.**: Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. *Int Braz Journal of Urology*. 2007 Jan-Feb; 33(1):25-32

78. Kouba E, Smith A, McRackan D, Wallen E, **Pruthi R.S.**: Watchful waiting for solid renal masses: insight into the natural history and the results of delayed intervention. *Journal of Urology*. 2007 Feb; 177(2):466-70
79. Tornehl C., Derksen JE, Maygarden S., Connolly AM, **Pruthi R.S.**: Bladder Leiomyoma Resection Facilitated by Abdominal Development of the Paravaginal Space. *Issues in Urology*. Jan/Feb 2007, p. 14-17.
80. Kouba E, Smith A, Derksen J.E., Gunn K, Wallen E, **Pruthi R.S.**: Efficacy and safety on en bloc ligation of the renal hilum during laparoscopic nephrectomy. *Urology*. 2007 Feb; 69(2):226-9
81. Kouba E. Hubbard J.S., Moore D., Wallen E., **Pruthi R.S.** Prospective evaluation of short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy. *BJU International*. *BJU Int*. 2007 Jan; 99(1):72-6.
82. Kouba E. Wallen E., **Pruthi R.S.** Uroscopy by Hippocrates and theophilus: prognosis versus diagnosis. *Journal of Urology*. 177:50-2, 2007.
83. **Pruthi R.S.**, Hubbard J.S., Kouba E., Wallen E.M.: Androgen-Independent Prostate Cancer Treated with Resection of the Solitary Metastatic Site. *Urologia Internationalis*. (accepted/ in press 6/06).
84. **Pruthi R.S.**, Kouba E., Hubbard JS, Wallen E Incisional Hernia in a 12 mm Non-Bladed Trocar Site Following Laparoscopic Nephrectomy. *Urologia Internationalis* 2007; 79:276-9.
85. Kouba E., Evans A., Gaston K.E., Lavelle J.P., **Pruthi R.S.**: From Simple Urinary Tract Infection to Transitional Cell Carcinoma of the Bladder: Evaluation of Patients with Irritative Voiding Symptoms. *Issues in Urology* pp. 43-48. March/April, 2007
86. **Pruthi R.S.** and Wallen E.: Surgery in Motion: Robotic-assisted laparoscopic radical cystectomy *European Urology* (paper and video) (epub ahead of print 3/07).
87. Wallen E., **Pruthi R.S** The burden of kidney cancer in America: the urologic diseases of America project. *Journal of Urology* 2007 Jun; 177:2006-18.
88. **Pruthi R.S.**: Editorial Comment in re: Stopping smoking might reduce tumor recurrence in non-muscle invasive bladder cancer. *BJU Int*. 2007 April 5 (epub ahead of print).
89. Miller J., Kouba E., Smith A., Wallen E., **Pruthi R.S** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing Robotic-assisted laparoscopic radical prostatectomy vs. open radical prostatectomy. *Journal of Urology* 2007 Sep; 178(3):854-9.
90. Kouba E., Lentz A., Sands M., Wallen E., **Pruthi R.S** A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. *Journal of Urology* 2007 Sep; 178(3):945-9

91. **Pruthi R.S.** and Wallen E Robotic-assisted laparoscopic radical cystectomy: operative and pathologic outcomes. *Journal of Urology* 2007 Sep; 178(3):814-8.
92. Kouba E., Lentz A., Sands M., Wallen E., **Pruthi R.S.** Stomal Complications in Patients Undergoing Radical Cystectomy with Ileal Conduit Urinary Diversion for Bladder Cancer. *Journal of Urology* 2007 Sep; 178(3):950-4.
93. Kouba E., Wallen E., **Pruthi R.S.** Gum chewing stimulate recovery of bowel function in patients undergoing cystectomy and urinary diversion. *Urology* (accepted 8/07).
94. **Pruthi R.S.**, Bhalani V., Wallen E., Expectant management of patients with low-risk superficial bladder cancer. *Journal of Urology*. (publication date 3/08).
95. Kouba E., Wallen E. **Pruthi R.S.** The Management of Ureteral Obstruction due to Advanced Malignancy: Optimizing Therapeutic and Palliative Outcomes. *Journal of Urology* (accepted 9/07).
96. Hall MC, Chang SS, Dalbagni G, **Pruthi R.S.**, Schellhammer P., Seigne J, Skinner EC, Wolf JS. Guideline for the Management of Nonmuscle Invasive Bladder Cancer: 2007 Update. *Journal of Urology*. 2007 Dec; 178:2314-30.
97. **Pruthi R.S.**, Hubbard JS, Kouba E, Wallen E. Androgen-independent prostate cancer treated with resection of the solitary metastatic site. *Urologia Internationalis*. 2007; 79(4):371-3.

Book Chapters

- Fielding J., **Pruthi R.S.** Imaging of nephrolithiasis, urinary tract infections and their complications. In *Evidence-Based Imaging: Optimizing Imaging in Patient Care* Medina, L. Santiago; Blackmore, C. Craig (Eds.) 2006. Springer, New York.
- Pearson M., **Pruthi R.S.** Quality of Life in QOL in men undergoing radical prostatectomy. In *Handbook of Disease Burdens and Quality of Life Measures*. V. Preedy (Ed.) 2008. Springer, New York
- Ramirez M., **Pruthi R.S.**, deVere-White R. Pelvic Lymphadenectomy. In *Glenn's Urologic Surgery* (7th edition). Graham S. and Keane T. (Eds.) 2008. Lippincott Williams & Wilkins

Videos:

Chun J., **Pruthi R.S.**: Laparoscopic Partial Nephrectomy. Baxter Incorporated. April, 2003.

Pruthi R.S., Wallen E.M.: Robotic-assisted laparoscopic radical cystoprostatectomy. *Surgery-in-Motion*. *European Urology*. (Epub ahead of print 3/07).

Pruthi R.S., Wallen E.M.: Robotic-assisted laparoscopic radical cystoprostatectomy. Intuitive Corporation. In production (9/2007).

Presentations:

1. **Pruthi, R.S.**, Farouk, M., Meyers, W.C.: The effect of octreotide on liver regeneration in the rat. 22nd Annual AOA Original Studies Symposium. March 28, 1991. Durham, North Carolina.
2. **Pruthi, R.S.**, Farouk, M., Meyers, W.C.: Somatostatin analogue inhibits hepatic regeneration. Clinical Congress of the American College of Surgeons. October 21, 1991. Chicago, Illinois.
3. **Pruthi, R.S.**, Angell S.A., Freiha, F.S.: Papillary thyroid carcinoma found in the kidney. 22nd Annual Northern California Residents Conference. March 4, 1995. Stanford, California. (Winner, First Prize)
4. **Pruthi, R.S.**, Kurtzig, K., Kessler, R.: Long-term follow-up of patients undergoing internal spermatic vein ligation for infertility. 24th Annual Symposium on Diseases of the Urinary Tract. March 14, 1996. Palo Alto, California.
5. **Pruthi, R.S.**, and Stamey, T.A.: The use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy. 23rd Annual Northern California Residents Conference. April 27, 1996. Sacramento, California. (Winner, Second Prize)
6. **Pruthi, R.S.**, Angell, S.A., Dubocq, F., Merguerian, P.A., Shortliffe, L.D.: The use of renal parenchymal area in children with vesicoureteral reflux. American Academy of Pediatrics -- Section on Urology. October 27, 1996. Boston, Massachusetts.
7. **Pruthi, R.S.**, Tu, I-P, Johnstone, I., Stamey, T.A.: PSA doubling times in patients who fail radical prostatectomy: correlation with histology of the primary cancer. American Urological Association. April 16, 1997. New Orleans, Louisiana.
8. **Pruthi, R.S.**, and Stamey, T.A.: PSA doubling times and times to PSA recurrence in patients who fail radical prostatectomy. 24th Annual Northern California Residents Conference. May 3, 1997. San Francisco, California. (Winner, First Prize)
9. Kang, J., Mohler, J.L., **Pruthi, R.S.**: Unilaterally-positive sextant biopsies useful for predicting final pathology. American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.
10. Kang, J., Mohler, J.L., **Pruthi, R.S.**: Impact of positive apical biopsies on unfavorable pathological outcomes in prostate cancer. American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.
11. Kang, J., Mohler, J.L., **Pruthi, R.S.**: Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. American Urological Association, Southeastern Section. April 1, 2001. New Orleans, Louisiana.

12. Kang, J., Mohler, J.L., Maygarden S.J., **Pruthi, R.S.**: Impact of positive biopsy location on final tumor extent and unfavorable pathological outcomes in prostate cancer. American Urological Association. June 6, 2001. Anaheim, California.
13. Derksen E., **Pruthi, R.S.**: COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. American Urological Association, Southeastern Section. March 3, 2002. Naples, Florida.
14. Gaston K, **Pruthi, R.S.**: Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve. American Urological Association, Southeastern Section. March 3, 2002. Naples, Florida.
15. Derksen E., **Pruthi, R.S.**: COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. American Urological Association, May 25, 2002. Orlando, California.
16. Gaston K, **Pruthi, R.S.**: The use of erythropoietin in patients undergoing prostatectomy: effects on hematocrit, transfusion rates, and quality of life. American College of Surgeons Clinical Congress, October 8, 2002. San Francisco, California.
17. Moliterno J, Evans A, Ornstein DK, Mohler JL, **Pruthi R.S.** Characterization of PSA doubling times in patients who have failed radical prostatectomy. American College of Surgeons Clinical Congress, October 8, 2002. San Francisco, California.
18. Chun J., **Pruthi R.S.**: The use of fibrin tissue sealants during laparoscopic partial nephrectomy. . American Urological Association, Southeastern Section. March 28, 2003. Savannah, Georgia.
19. Gaston K., Lee K., **Pruthi R.S.**: The impact of a siblings diagnosis of prostate cancer on prostate cancer knowledge, screening behavior, and other health-related activities. American Urological Association, Southeastern Section. March 30, 2003. Savannah, Georgia.
20. Derksen J.E., Fitzsimmons N., Ornstein D., **Pruthi R.S.**: Early urethral catheter removal after radical retropubic prostatectomy. American Urological Association, Southeastern Section. March 27, 2003. Savannah, Georgia.
21. Derksen J.E., Fitzsimmons N., Ornstein D., **Pruthi R.S.**: Factors affecting length of stay after radical retropubic prostatectomy. American Urological Association, Southeastern Section. March 30, 2003. Savannah, Georgia.
22. Moliterno J., Tenkhenekov S., Ornstein D., **Pruthi R.S.**: Comparison of clinical and pathological staging of bladder cancer. American Urological Association, Southeastern Section. March 28, 2003. Savannah, Georgia.
23. Moliterno J., Tenkhenekov S., Ornstein D., **Pruthi R.S.**: Incidental Finding of Prostate Cancer at Cystoprostatectomy. American Urological Association. April 30, 2003. Chicago, Illinois.
24. Ornstein DK, Fusaro V., Ross S., Hitt BA, Grigson G, Bell HA, **Pruthi R.S.**, Liotta LA, Petricoin EF: Analysis of serum proteomic profiles with Seldi-TOF and artificial intelligence

pattern-based recognition can help determine the need for prostate biopsy. April 29, 2003. Chicago, Illinois.

25. **Pruthi R.S.:** COX-2 inhibitors in PSA-recurrent prostate cancer: a pilot study. Innovators in Urology International Meeting. Amsterdam, The Netherlands. June 6, 2003.
26. Derksen J.E., Fitzsimmons N., Ornstein D., **Pruthi R.S.:** Early urethral catheter removal after radical retropubic prostatectomy. American College of Surgeons Clinical Congress, October 20, 2003. Chicago, Illinois.
27. Gaston K., Lee K., **Pruthi R.S.:** Impact of race, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in sibling of patients with prostate cancer. American College of Surgeons Clinical Congress, October 20, 2003. Chicago, Illinois.
28. **Derksen J.E., Pruthi R.S.:** The use of the COX-2 inhibitor celecoxib in PSA-recurrent prostate cancer (CaP) after radiation therapy or radical prostatectomy: 12 month follow-up. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
29. McLaughlin S., Shephard J., Wallen E.M., **Pruthi R.S.:** Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
30. McLaughlin S., Wallen E.M., **Pruthi R.S.:** Expression of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCCa). Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
31. Gaston K., Lee K., **Pruthi R.S.:** Impact of a Sibling's Diagnosis of Prostate Cancer (CaP) on Prostate Cancer Knowledge, Screening Behavior, and other Health-related Activities. Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
32. Gaston K., Lee K., **Pruthi R.S.:** Impact of Race, Age, Income, and Residence on Prostate Cancer (CaP) Knowledge, Screening Behavior, and Health Maintenance in Siblings of Patients with CaP Society of Urologic Oncology, December 5, 2003. Bethesda, Maryland.
33. McLaughlin S., Shephard J., Wallen E.M., **Pruthi R.S.:** Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. American Urological Association, Southeastern Section. March 26, 2004. Aruba.
34. McLaughlin S., Chun J., Richman M., **Pruthi R.S.:** Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy. American Urological Association, Southeastern Section. March 26, 2004. Aruba.
35. McLaughlin S., Chun J., Richman M., **Pruthi R.S.:** Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. American Urological Association, Southeastern Section. March 28, 2004. Aruba.

36. Tornehl C., Kouba E., Wallen E., **Pruthi R.S.**: Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal bond integrity in a live porcine animal model. American Urological Association, Southeastern Section. March 26, 2004. Aruba.
37. Tornehl C., Kouba E., Wallen E., **Pruthi R.S.** Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. American Urological Association, Southeastern Section. March 25, 2004. Aruba.
38. McLaughlin S., Shephard J., Wallen E.M., **Pruthi R.S.**: Comparison of clinical and pathological staging in patients undergoing primary versus delayed radical cystectomy for bladder cancer. American Urological Association. May 9, 2004. San Francisco, California.
39. McLaughlin S., Funkhouser W.K., Wallen E.M., **Pruthi R.S.**: Expression of Cyclooxygenase-2 in human renal cell carcinoma. American Urological Association. May 10, 2004. San Francisco, California.
40. Tornehl C., Kouba E., Wallen E., **Pruthi R.S.**: Partial nephrectomy with fibrin glue repair: measurement of vascular and pelvicaliceal bond integrity in a live porcine animal model. American Urological Association. May 10, 2004. San Francisco, California.
41. Tornehl C., Gaston K.E., Carson C.C, Wallen E., **Pruthi R.S.**: Impact of Race, Age, Income, and Residence on Prostate Cancer (CaP) Knowledge, Screening Behavior, and Health Maintenance in Siblings of Patients with CaP American Urological Association. May 12, 2004. San Francisco, California.
42. Kang, J., **Pruthi, R.S.**: Comparison of grade and stage in African American and Caucasian patients with prostate cancer: evaluation of clinical, biopsy, and surgical pathology. American Urological Association, Chief Resident Meeting. May 13, 2004. San Francisco, California.
43. Hawke NA, **Pruthi R.S.**, Funkhouser WK, Baldwin AS. Phosphorylated serine 536 as an indicator of NF (B activity in prostate cancer. Keystone Symposia. January 11, 2004. Colorado.
44. **Pruthi R.S.**, Derksen JE. A phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Society of Clinical Oncology. June 6, 2004. New Orleans, Louisiana.
45. Baggstrom MQ, Rosenman J, **Pruthi R.S.**, Whang Y., Goyal L, Grigson G, Godley P. A phase II trial of neo-adjuvant docetaxel (D) and estramustine (E) in patients with high risk/locally advanced prostate cancer. American Society of Clinical Oncology. June 6, 2004. New Orleans, Louisiana.
46. Tornehl C., Kouba E., Wallen E., **Pruthi R.S.** Initial experience with fibrin tissue sealants during laparoscopic partial nephrectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.

47. McLaughlin S., Chun J., Richman M., **Pruthi R.S.**: Potential role of initial incision of the lateral pelvic fascia, development of a perirectal pocket, and early ligation of the vascular pedicles in reducing positive margins during radical prostatectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.
48. Derksen J.E., **Pruthi R.S.**, Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American College of Surgeons. October 11, 2004. New Orleans, Louisiana.
49. Hubbard J.S., Stefaniak H., Moliterno J., Wallen E., **Pruthi R.S.**, Incidental Finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
50. Stefaniak H., Wallen E., **Pruthi R.S.** Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
51. Hubbard J.S., Wallen E., **Pruthi R.S.** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing radical prostatectomy (RP). American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
52. Stefaniak H., Wallen E., **Pruthi R.S.** The use of the COX-2 inhibitor celecoxib to reduce perioperative pain associated with radical retropubic prostatectomy (RRP). American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
53. Evans A., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Costs and surgical outcomes associated with radical cystectomy: changes over the past decade. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
54. Evans A., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Complications and reasons for prolonged stay in patients undergoing radical cystectomy utilizing a perioperative pathway. American Urological Association, Southeastern Section. March 4, 2005. Charleston, South Carolina.
55. Derksen J.E., Grigson G., Wallen E., **Pruthi R.S.**, Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
56. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Safe and effective application of laparoscopic partial nephrectomy for small renal masses: duplication of open principles and practices. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
57. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Hand Assisted Laparoscopic Nephrectomy for Large Renal Masses. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.

58. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S** Efficacy and Safety of En Bloc Ligation of the Renal Hilum at the time of Laparoscopic Nephrectomy: Review of 62 consecutive cases. American Urological Association, Southeastern Section. March 5, 2005. Charleston, South Carolina.
59. Stefaniak H., Carson C.C., **Pruthi R.S.**, Wallen E., Tadalafil therapy beginning on post-operative day one preserves potency in men undergoing radical prostatectomy. American Urological Association, Southeastern Section. March 3, 2005. Charleston, South Carolina.
60. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Safe and effective application of laparoscopic partial nephrectomy for small renal masses: duplication of open principles and practices. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
61. Stefaniak H., Wallen E., **Pruthi R.S.** Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
62. Hubbard J.S., Stefaniak H., Moliterno J., Wallen E., **Pruthi R.S.**, Incidental Finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. Society of Urologic Oncology. December 3, 2004. Bethesda, Maryland.
63. Derksen J.E., Grigson G., Wallen E., **Pruthi R.S.**, Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. American Urological Association, May 22, 2005. San Antonio, Texas.
64. Santa-Cruz R.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S** Efficacy and Safety of En Bloc Ligation of the Renal Hilum at the time of Laparoscopic Nephrectomy: Review of 62 consecutive cases. American Urological Association, May 22, 2005. San Antonio, Texas.
65. Hubbard J.S., Wallen E., **Pruthi R.S.** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing radical prostatectomy (RP). American Urological Association, May 25, 2005. San Antonio, Texas.
66. Stefaniak H., Wallen E., **Pruthi R.S.** Neoadjuvant Docetaxel and Estramustine Followed by Radical Prostatectomy or Radiation Therapy for Patients with High-Risk Prostate Cancer. American Urological Association, May 21, 2005. San Antonio, Texas.
67. Stefaniak H., Carson C.C., **Pruthi R.S.**, Wallen E., Tadalafil therapy beginning on post-operative day one preserves potency in men undergoing radical prostatectomy. American College of Surgeons, October 16, 2005. San Francisco, California.
68. Hubbard J.S., Derksen J.E., Moliterno J., Wallen E., **Pruthi R.S.** Hand Assisted Laparoscopic Nephrectomy for Large Renal Masses. American College of Surgeons, October 16, 2005. San Francisco, California.
69. **Pruthi R.S.**, Carson C.C. COX-2 inhibitors in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Urologic Research Society, November 10, 2005. Boston Massachusetts.

70. Thomasch J., Kouba E., Hickerson A., Wallen E., **Pruthi R.S** Impact of Race on time to androgen independence and subsequent biochemical progression in men with advanced prostate cancer. Society of Urologic Oncology. December 2, 2005. Bethesda, Maryland.
71. McRackan D, Kouba E., Smith A., Wallen E., **Pruthi R.S** Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
72. Wallen E., **Pruthi R.S** The burden of kidney cancer in America: the urologic diseases of America project. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico
73. Stefaniak H., Carson C.C., **Pruthi R.S.**, Wallen E., Tadalafil therapy beginning on post-operative day one preserves potency in men undergoing radical prostatectomy. – preliminary one-year results. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico
74. Hickerson A., Leese P., Moore D., Wallen E., Mohler J., **Pruthi R.S.:** Watchful waiting for patients with locally-advanced and node-positive prostate cancer: biochemical and clinical outcomes. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico
75. Hickerson A., Leese P., Moore D., Wallen E., Mohler J., **Pruthi R.S.:** Impact of race on treatment selection and disease progression in men who choose observation for clinically-localized prostate cancer. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico
76. McRackan D, Evans A., Carson C., Wallen E., Michell P., **Pruthi R.S** An evaluation of prostate cancer knowledge in patients with prostate cancer: impact of demographic and socioeconomic variables. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
77. McRackan D, Evans A., Carson C., Wallen E., Michell P., **Pruthi R.S** An evaluation of prostate cancer knowledge in patients with prostate cancer in patients with prostate cancer and their partners. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
78. Thomasch J., Kouba E., Hickerson A., Wallen E., **Pruthi R.S** Impact of Race on time to androgen independence and subsequent biochemical progression in men with advanced prostate cancer. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
79. Hickerson A., Kouba E., Wallen E., **Pruthi R.S.:** Evaluation of the routine use of metocloperamide in patients undergoing radical cystectomy and urinary diversion. . American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico

80. McRackan D, Kouba E., Wallen E., **Pruthi R.S** Recent experience of surgical management of renal masses: the evolution of laparoscopic approaches in clinical practice. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
81. Hickerson A., **Pruthi R.S.**, Wallen E.: Laparoscopic retroperitoneal lymph node dissection for low-stage testicular cancer: challenges and benefits. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.
82. Wallen E., **Pruthi R.S** The burden of kidney cancer in America: the urologic diseases of America project. American Urological Association. May 22, 2006. Atlanta, Georgia
83. McRackan D, Kouba E., Smith A., Wallen E., **Pruthi R.S** Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American Urological Association. May 21, 2006. Atlanta, Georgia
84. Hubbard J.S., Stefaniak H., Moliterno J., Wallen E., **Pruthi R.S.**, Incidental Finding of prostate cancer at cystoprostatectomy: changes in incidence in the PSA era. American Urological Association. May 21, 2006. Atlanta, Georgia
85. McRackan D, Kouba E., Smith A., Wallen E., **Pruthi R.S** Expectant management of small renal masses: Does a delay in therapy pose a clinical or pathological risk to the patient? American College of Surgeons, October 10, 2006. Chicago, Illinois.
86. Hickerson A., Kouba E., Wallen E., **Pruthi R.S.:** The Impact of Race and Gender in Patients Undergoing Radical Cystectomy for Bladder Cancer. American College of Surgeons, October 10, 2006. Chicago, Illinois.
87. Lentz A., Wallen E., **Pruthi R.S** Robotic-assisted laparoscopic radical cystectomy: initial experience and operative outcomes. Society of Urologic Oncology. December 2, 2006. Bethesda, Maryland.
88. Miller J., Kouba E., Smith A., Wallen E., **Pruthi R.S** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing Robotic-assisted laparoscopic radical prostatectomy (RALRP) VS. open radical prostatectomy (ORP). Society of Urologic Oncology. December 2, 2006. Bethesda, Maryland.
89. Lentz A., Wallen E., **Pruthi R.S** Robotic-assisted laparoscopic radical cystectomy: initial experience and operative outcomes. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
90. Lentz A., Sands M., Kouba E., Wallen E., **Pruthi R.S** Stomal complications in patients undergoing radical cystectomy and ileal conduit urinary diversion for bladder cancer. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
91. Miller J., Bhalani V., Wallen E., **Pruthi R.S** Expectant management of patients with low-risk superficial bladder cancer. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.

92. Lentz A., Smith A., Kouba E., Wallen E., **Pruthi R.S** Gender-Dependent Associations Between Body Composition in patients with Renal Cell Carcinoma (RCC). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
93. Lentz A., Smith A., Kouba E., Wallen E., **Pruthi R.S** Impact of Surgical Treatment of Renal Carcinoma on Renal Function and Blood pressure: A Race- and Age-Dependent Association. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
94. Miller J., Kouba E., Smith A., Wallen E., **Pruthi R.S** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing Robotic-assisted laparoscopic radical prostatectomy (RALRP) VS. open radical prostatectomy (ORP). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
95. Miller J., Swords K., Carson CC, Lavelle J., Wallen E., **Pruthi R.S.** Diagnostic rates and other outcomes based on initial versus repeat biopsy in a modern cohort of men undergoing an extended biopsy (10-12 core) scheme. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
96. Miller J., Anderson A., Fielding J., Kouba E., Wallen E., **Pruthi R.S.** Accuracy of MR and CT cross sectional imaging in the staging of invasive bladder cancer: a prospective study blinded to clinical outcome. American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
97. Kouba E., Miller J., Wallen E., **Pruthi R.S.** Characterization of Acute Phase Inflammation in Men Undergoing Robotic-Assisted Laparoscopic Radical prostatectomy (RALRP). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
98. **Pruthi R.S.**, Wallen E., Robotic-assisted laparoscopic radical cystectomy (video). American Urological Association, Southeastern Section. March 10, 2007. Orlando, Florida.
99. Carson CC 3rd, Coward M., Simhan J., **Pruthi R.S.** Prostate cancer in hypogonadal men on testosterone replacement therapy. American Urological Association, Southeastern Section. March 8, 2007. Orlando, Florida.
100. Lentz A, Sands M, Kouba E, Wallen E, **Pruthi R.S.** Impact of marital status in patients undergoing radical cystectomy for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.
101. Lentz A, Sands M, Kouba E, Wallen E, **Pruthi R.S.** Stomal complications in patients undergoing radical cystectomy and ileal conduit urinary diversion for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.
102. Lentz A, Sands M, Kouba E, Wallen E, **Pruthi R.S.** A comparison of the Bricker versus Wallace ureteroileal anastomosis in patients undergoing urinary diversion for bladder cancer. American Urological Association, May 20, 2007, Anaheim, California.
103. Miller J, Smith A, Kouba E, Wallen E, **Pruthi R.S.** Prospective evaluation of short-term impact and recovery of health-related quality of life (HRQOL) in men undergoing robotic-

assisted laparoscopic radical prostatectomy vs open radical prostatectomy (ORP). American Urological Association, May 20, 2007, Anaheim, California.

104. Miller J, Smith A, Kouba E, Wallen E, **Pruthi R.S.** Gender-dependent associations between body composition in patients with renal cell carcinoma (RCC). American Urological Association, May 21, 2007, Anaheim, California.
105. Miller J, Smith A, Gunn K, Kouba E, Wallen E, **Pruthi R.S.** Impact of surgical treatment of renal carcinoma on renal function and blood pressure: A race- and age-dependent association. American Urological Association, May 22, 2007, Anaheim, California.
106. Miller J, Bhalani V, Baldwin N, Kouba E, Wallen E, **Pruthi R.S.** Expectant management of patients with low-risk superficial bladder cancer. American Urological Association, May 22, 2007, Anaheim, California.
107. Miller J., Swords K., Carson CC, Lavelle J., Wallen E., **Pruthi R.S.** Diagnostic Rates And Other Outcomes Based On Initial Versus Repeat Biopsy In A Cohort Of Men Undergoing An Modern Biopsy (10-12 Core) Scheme. American College of Surgeons, October 9, 2007. New Orleans, Louisiana.
108. Lentz A, Sands M, Kouba E, Wallen E, **Pruthi R.S.** Clinical Usefulness Of Serum Ca 125 Levels In Patients Undergoing Radical Cystectomy For Transitional Cell Carcinoma Of The Bladder. American College of Surgeons, October 9, 2007. New Orleans, Louisiana.
109. Pearson M., Nix J., Kim W., Grigson G., Wallen EM, **Pruthi R.S.** A Phase II Study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: preliminary results. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.
110. Pearson M., Nix J., Wallen EM, **Pruthi R.S.** The impact of bladder neck sparing modification on surgical and functional outcomes after robotic-assisted laparoscopic radical prostatectomy. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.
111. Nix J., Pearson M., Wallen EM, **Pruthi R.S.** Trends in cystectomy use in octogenarians with bladder cancer. Society of Urologic Oncology. December 1, 2007. Bethesda, Maryland.

Invited Lectures

“Debate on the management of small renal masses: Observation” Northeastern Section of the American Urological Association. September 9, 2007. Rochester, New York.

“Management of Invasive Bladder Cancer” Centennial Congress of the Societe Internationale d’Urologie (SIU). September 4, 2007. Paris, France.

“The multidisciplinary approach to urologic oncology.” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“The robotic cystectomy program at UNC.” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“Bone complications and their treatment in the prostate cancer patient” Fifth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 15, 2007. Chapel Hill, North Carolina.

“Health disparities in prostate cancer” Texas health disparities conference. May 31, 2007. Fort Worth, Texas.

“Bone complications and their treatment in the prostate cancer patient.” Alamance Regional Cancer Center. April 30, 2007. Burlington, North Carolina.

“Emerging Concepts in the Multidisciplinary treatment of high risk prostate cancer.” Kugelman Cancer Center Urology-Oncology Rounds. April 30, 2007. Pensacola, Florida.

“Managing skeletal complications in the prostate cancer patient.” Rowan County Oncology Rounds. April 17, 2007. Salisbury, North Carolina.

“Bone complications and their treatment in the prostate cancer patient.” Rex Cancer Center Rounds. April 11, 2007. Raleigh, North Carolina.

“Emerging Concepts in the Treatment of Invasive Bladder Cancer.” First Annual Urology Congress. April 6, 2007. San Francisco, California.

“Management of High-risk Patients with Prostate Cancer”. Duke-UNC Urologic Oncology Forum. March 29, 2007. Durham, North Carolina.

Moderator Bladder Cancer Podium Session. American Urological Association, Southeastern Section. March 9, 2007. Lake Buena Vista, Florida.

“Emerging Concepts in the Treatment of Bladder Cancer including the Potential of Robotic Cystectomy” Department of Urology Grand Rounds. WakeMed Medical Center. February 21, 2007. Raleigh, North Carolina.

“Bone complications and their treatment in the prostate cancer patient.” Western Carolina Oncology Society. December 1, 2006. Asheville, North Carolina.

“Modern Concepts in the Treatment of Bladder Cancer including the Potential of Robotic Cystectomy” Department of Urology Grand Rounds. Duke University. October 22, 2006. Durham, North Carolina.

“Understanding bone complications and their treatment in the prostate cancer patient.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Modern Approaches to the Treatment of Bladder Cancer.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Complex laparoscopic renal surgery.” Fourth Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 23, 2006. Chapel Hill, North Carolina.

“Promise and potential of COX-2 inhibitors in Urology.” Visiting Professor, Department of Urology Grand Rounds. Medical College of Georgia. June 22, 2006. Augusta, Georgia.

“Modern Approaches to the Treatment of Prostate Cancer.” Oncology Grand Rounds, Spartanburg Regional Medical Center. May 3, 2006, Spartanburg, North Carolina.

“Prostate Cancer Clinical Trials and the Evolving Area of Prostate Cancer Therapy.” Oncology Rounds, New Hanover Regional Medical Center. March 21, 2006, Wilmington, North Carolina.

Moderator Prostate Cancer Poster Session. American Urological Association, Southeastern Section. March 2, 2006. San Juan, Puerto Rico.

“Understanding bone complications and their treatment in the prostate cancer patient.” Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17, 2005. Chapel Hill, North Carolina.

“COX-2 inhibitors in urology: current peril or future promise?” Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17, 2005. Chapel Hill, North Carolina.

“Complex laparoscopic renal surgery.”. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 18, 2005. Chapel Hill, North Carolina.

“Prostate Cancer Clinical Trials at The University of North Carolina at Chapel Hill.” Duke Prostate Cancer Symposium. April 9, 2005, Durham, North Carolina.

“Modern approaches to the Treatment of Prostate Cancer.” Legends Annual Meeting. The University of North Carolina at Chapel Hill. April 3, 2005, Chapel Hill, North Carolina.

Moderator Prostate Cancer Poster Session. American Urological Association, Southeastern Section. March 6, 2005. Charleston, South Carolina.

“Robotics, laparoscopy, and other novel surgical approaches to the treatment of prostate cancer.” Annual Oncology Nursing Forum at the University of North Carolina. The University of North Carolina at Chapel Hill. March 15, 2005, Chapel Hill, North Carolina.

“Modern Concepts in the Treatment of Prostate Cancer.” Department of Surgery Grand Rounds, University of North Carolina. January 14, 2005.

“The role of COX-2 inhibitors in urologic oncology.” Urologic Oncology Research Disease Group Rounds, Department of Urology. University of Iowa. November 19, 2004. Iowa City, Iowa.

“Promise and potential of COX-2 inhibitors in urology.” Visiting Professor, Department of Urology. University of Iowa. November 18, 2004. Iowa City, Iowa.

“The role of COX-2 inhibitors in urologic oncology.” Piedmont Urological Society. August 9, 2004. Winston-Salem, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Eastern Shore Medical Society. April 21, 2004. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Department of Urology Grand Rounds. Hopkins-Bayview Medical Center. April 20, 2004. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Department of Urology Grand Rounds. University of Maryland. April 19, 2004. Baltimore, Maryland.

Moderator – Laparoscopy Poster Session. American Urological Association, Southeastern Section. March 26, 2004. Aruba.

“Urology Review”: American Academy of Physicians Assistants Annual Review Course. February 24, 2004.

“The role of COX-2 inhibitors in urologic oncology.” Visiting Professor, Department of Urology Grand Rounds. Stanford University. February 20, 2004. Stanford, California.

“The role of COX-2 inhibitors in oncology.” Department of Anesthesia, Pain Service Grand Rounds. Stanford University. February 20, 2004. Stanford, California.

“The multidisciplinary approach to urologic oncology.” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“Concepts and Controversies in the Management of Invasive Bladder Cancer” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“Laparoscopic Renal Surgery” Symposium on the Multidisciplinary Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13, 2004. Chapel Hill, North Carolina.

“The role of COX-2 inhibitors in urologic oncology.” Department of Surgery Grand Rounds, University of North Carolina. January 14, 2004. Chapel Hill, North Carolina.

“The multidisciplinary approach to urologic oncology.” Advances in Oncology Nursing Symposium. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. November 12, 2003. Chapel Hill, North Carolina.

“Modern concepts in the treatment of prostate cancer.” Oncology Grand Rounds. Watauga Memorial Hospital. October 17, 2003.

“Modern concepts in the treatment of prostate cancer.” Medical Grand Rounds. Gastonia Memorial Hospital. August 17, 2003.

“The role of COX-2 inhibitors in urologic oncology.” Making a Difference in Oncology. Sponsored by Moffitt Cancer Center, The University of South Florida. April 26, 2003. Phoenix, Arizona.

“The role of COX-2 inhibitors in urologic oncology.” Oncology Grand Rounds. The University of Maryland. March 6, 2003. Baltimore, Maryland.

“The role of COX-2 inhibitors in urologic oncology.” Grand Rounds. Saint Josephs Hospital. March 5, 2003. Baltimore, Maryland

“The role of COX-2 inhibitors in urologic oncology.” Eastern Shore Medical Society. March 6, 2003. Baltimore, Maryland.

“The Role of Laparoscopy in Urologic Oncology”: Tri-County Urology Meeting. Fayetteville, North Carolina. March 11, 2003.

“Management of Rising PSA after definitive therapy for prostate cancer.” Symposium on the Multidisciplinary Advances in the Treatment of Prostate Cancer. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 1, 2003. Chapel Hill, North Carolina.

“Concepts and Controversies in the Management of Invasive Bladder Cancer”: Eastern Carolina Urological Association. September 17, 2002. Greenville, North Carolina.

“Laparoscopic Nephrectomy, Partial Nephrectomy and Renal Cyst Marsupialization: Surgical Technique”: Invited Lecturer, Carolinas Laparoscopy & Advanced Surgery Program. September 6, 2002. Charlotte, North Carolina.

“Management of Invasive Bladder Cancer” Department of Surgery Grand Rounds, University of North Carolina. August 6, 2002. Chapel Hill, North Carolina.

“Current Controversies in the Management of Invasive Bladder Cancer”: Carolina Urological Association 72nd Annual Meeting. August 30-September 1, 2002. Wrightsville Beach, North Carolina.

“Laparoscopic Nephrectomy and Renal Cyst Marsupialization: Surgical Technique”: Urology Grand Rounds. June 29, 2002. Wilmington, North Carolina.

“Laparoscopic Nephrectomy: History and Contemporary Applications”: Urology Grand Rounds. Dartmouth-Hitchcock Medical Center. June 11, 2002. Hanover, New Hampshire.

“Current Concepts in Urinary Diversion”: Society of University Urological Residents 37th Annual Meeting. May 23-24, 2002. Orlando, Florida.

“PSA and Prostate Cancer”: Department of Medicine Grand Rounds, University of North Carolina. May 6, 2002. Chapel Hill, North Carolina.

“The Role of Laparoscopy in Urologic Oncology”: Wake County Urology Meeting. May 15, 2002. Raleigh, North Carolina.

“Urology Review”: American Academy of Physicians Assistants Annual Review Course. February 24, 2002.

“PSA and Prostate Cancer”: Department of Family Medicine Grand Rounds, University of North Carolina. September 6, 2001. Chapel Hill, North Carolina

“Prostate Disease and Prostate Cancer” Westcare (UNC AHEC) Teleconference/Grandrounds. August 21, 2001. Chapel Hill North Carolina (teleconference).

“PSA and Prostate Cancer”: Randolph County Medical Association. January 22, 2001. Asheboro, North Carolina.

“Surgical Treatment of Renal Cell Carcinoma: Past, Present, and Future”: National Kidney Cancer Association. October 14, 2000. Research Triangle Park, North Carolina.

“The Role of Laparoscopy in Urologic Oncology”: Triad Urological Society. August 9, 2000. Winston-Salem, North Carolina.

“Surgical Treatment of Prostate Cancer: Indications, Techniques, and Outcomes”: Department of Surgery Grand Rounds, University of North Carolina. June 23, 2000, Chapel Hill, North Carolina.

“Prostate Cancer Update”: Pender County Medical Association. April 3, 2000. Burgaw, North Carolina.

“PSA doubling times in patients who fail radical prostatectomy: correlation with histology of the primary cancer”: Department of Urology Grand Rounds, Louisiana State University. March 30, 1999. Shreveport, Louisiana.

“PSA doubling times and times to PSA recurrence in patients who fail radical prostatectomy”: Division of Urology Grand Rounds, Dartmouth-Hitchcock Medical Center. February 27, 1999. Hanover, New Hampshire.

Courses

Course Director, Third Annual Landes Symposium on the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. June 17-18, 2005. Chapel Hill, North Carolina.

Course Co-director, Complex Laparoscopic Surgery in Urology. University of North Carolina, Chapel Hill, North Carolina. February 13-14, 2005.

Course Director, Advances in the Treatment of Genitourinary Cancers. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 13-14, 2004.

Course Director, Symposium on the Multidisciplinary Advances in the Treatment of Prostate Cancer. Lineberger Comprehensive Cancer Center. The University of North Carolina at Chapel Hill. February 1-2, 2003.

Course Director, Hand-Assisted and Laparoscopic Urology Course. Dartmouth-Hitchcock medical Center, Hanover, New Hampshire, June 10-11, 2002.

Course Co-Director Laparoscopic Renal Surgery. University of North Carolina, Chapel Hill, North Carolina. September 14-15, 2001.

Course Co-director, Laparoscopic Renal Surgery. University of North Carolina, Chapel Hill, North Carolina. June 13-14, 2001.

Local Course Director. Laparoscopic Renal Cryablation: Live surgery telecast. University of North Carolina, Chapel Hill, North Carolina. November 28, 2000.

Research

Co-Investigator. Rathmell W.K., Principal Investigator. A Phase II Trial of neoadjuvant sorafenib in patients with high risk renal cell carcinoma undergoing radical nephrectomy. Lineberger Comprehensive Cancer Center / Bayer / Onyx Inc. 11/06 – present.

Principal Investigator. A Phase II Study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Lineberger Comprehensive Cancer Center / OSI Inc., 6/05 – present.

Principal Investigator. The use of COX-2 inhibitors in PSA-recurrent prostate cancer. Lineberger Comprehensive Cancer Center / Pfizer Inc. 7/02 – present.

Principal Investigator. The use of the COX-2 inhibitor celecoxib in the chemoprevention of low-risk superficial bladder cancer. Lineberger Comprehensive Cancer Center / Pfizer Inc. 1/03 – present.

Principal Investigator. The role of COX-2 in renal cell carcinoma. Pfizer Inc. 1/03 – present.

Principal Investigator. Partial nephrectomy with fibrin glue repair: measurement of vascular and pelviciceal bond integrity in a live porcine and isolated abattoir animal model utilizing Tisseel fibrin tissue sealant. Baxter, Inc. 6/03 – 1/04.

Principal Investigator. A Phase II Trial of Plenaxis as Intermittent Therapy in Advanced Prostate Cancer. Lineberger Comprehensive Cancer Center / Praecis Inc. 3/05 – present.

Principal Investigator. Knowledge Characteristics in Pts with PCa and their partners (04SURG290). Lineberger Comprehensive Cancer Center. 7/04 – present.

Co-Investigator. Mohler JM., Principal Investigator. Understanding Racial Differences in Prostate Cancer. U.S. Department of Defense Prostate Cancer Research Program Consortium (3-year, \$9.9M) 8/1/04 – present.

Co-Principal Investigator; Smith M, Principal Investigator. A randomized Double Blind Placebo-Controlled Phase III Study of Early vs Standard Zolodronic Acid to Prevent Skeletal Related Events in Men with PCa –Metastatic to Bone. CALGB. 3/05 – present.

Co-investigator; Whang Y., Principal Investigator. A phase II study of Oral Once daily GW572016 (Lapatinib) in pts. With Hormone Refractory PCa (LCCC0505). Lineberger Comprehensive Cancer Center / GlaxoSmithKline. 3/05 – present.

Co-investigator; Wallen EM., Principal Investigator GST-Pi – 002 Quantitative GST-Pi Methylation BX tissue testing to Improve the Accuracy of Ca Detection in Men with High Risk Localized PCa Lineberger Comprehensive Cancer Center / Oncomethylone. 2/05 – present.

Co-Principal Investigator; Cote RJ, Principal Investigator. MVAC in organ-confined bladder cancer based on p53 status. National Cancer Institute. 11/1/97 – present.

Co-Principal Investigator; Lewis J, Principal Investigator. A multi-center randomized phase III study of adjuvant Oncophage (versus observation in patients with high risk of recurrence after surgical treatment for renal cell carcinoma. Antigenics Inc. 5/15/00 – 8/1/03

Co-Principal Investigator; Droller M., Principal Investigator. An open comparative within-patient controlled phase III multicenter study of Hexvix fluorescence cystoscopy and standard cystoscopy in the detection of carcinoma-in-situ in patients with bladder cancer. Photocure Inc. 8/15/00 – 1/1/04.

Co-Investigator. Meshel M., Principal Investigator. Decision-making and Uncertainty in Men Diagnosed with Prostate Cancer. National Institutes of Health. 6/03 – present.

Co-Investigator; Rathmell W.K., Principal Investigator. Phase II trial of Novel Vaccine in Patients with Metastatic Renal Cell Carcinoma. Merix Inc. 6/04 – present.

Co-Investigator; Rathmell W.K., Principal Investigator. Phase II trial of BAY-046 in Patients with Metastatic Renal Cell Carcinoma. Bayer Inc. 10/04 – present.

Co-investigator; Whang Y., Principal Investigator. A phase II trial of Atrasentin in men with metastatic, hormone-refractory prostate cancer. Abbott Laboratories. 6/02 – 6/03

Co- Investigator; Ornstein DK, Principal Investigator. SELDI analysis of serum proteins: a novel approach to improve early prostate cancer detection. Lineberger Comprehensive Cancer Center, UNC. 10/15/00 – 8/1/03.

Co-investigator. A phase II randomized-discontinuation study of oral CEP-701 in prostate cancer patients who have failed first-line hormonal therapy. TAP Holdings, Inc. 11/1/00 – 6/1/03.

Co-investigator: Godley P, Principal Investigator. The use of neoadjuvant chemotherapy in patients with high-risk bladder cancer. Lineberger Comprehensive Cancer Center / Aventis Pharmaceuticals. 5/02 – present.

Co-investigator; Mohler JL, Principal Investigator. A phase II chemoprevention trial of selenium and prostate cancer. Department of Defense. 6/30/00 – present.

Co-investigator; Schroeder J, Principal Investigator. Estimation of risks of development of renal cell carcinoma: evaluation of the effect of genetic polymorphisms in conjunction with environmental factors. National Institutes of Health. (submitted 10/04)

Honors/Awards

Jordan Scholar, Stanford University, 1984-1985

Thomas J. Watson Scholarship, Stanford University, 1984-1988

Pathology Research Scholar Award, Duke University, 1990-1991

American Liver Foundation Research Scholarship, Duke University, 1990-1991

Merck Book Prize, Duke University, 1992

Northern California Resident's Competition -- First Prize, Stanford University, 1995

Northern California Resident's Competition -- Second Prize, U.C. Davis, 1996

Northern California Resident's Competition -- First Prize, U.C.S.F., 1997

Faculty Teaching Award ("Attending of the Year"), Division of Urologic Surgery, 2000-01.

Excellence in Teaching Award, University of North Carolina School of Medicine, 2001.

Excellence in Teaching Award, University of North Carolina School of Medicine, 2002.

"Best Doctors in America", 2003-04, 2004-2005, 2005-2006, 2006-2007, 2007-2008

"Best Doctors in North Carolina", 2004-2005, 2005-2006, 2006-2007

T. Leon Howard Pyelogram Conference – Second Prize, SEUA Meeting, 2001

North Carolina Urology Seminar – Third Prize, Case Report, 2001

North Carolina Urology Seminar – Third Prize, Case Report, 2002

North Carolina Urology Seminar – First Prize, Research, 2002

North Carolina Urology Seminar – Second Prize, Research, 2003

North Carolina Urology Seminar – Third Prize, Case Report, 2004

North Carolina Urology Seminar – First Prize, Research, 2004

North Carolina Urology Seminar – Second Prize, Case Report, 2005

North Carolina Urology Seminar – First Prize, Research, 2005

North Carolina Urology Seminar – Second Prize, Research, 2006

Faculty Teaching Award ("Attending of the Year"), Division of Urologic Surgery, 2006-07.